Background {#Sec1}
==========

There are at least three filarial nematode diseases of public health importance in sub-Saharan Africa (SSA), namely, lymphatic filariasis (LF; caused in SSA by *Wuchereria bancrofti*), onchocerciasis (caused by *Onchocerca volvulus*), and loiasis (caused by *Loa loa*). Infection with these parasites is responsible for significant morbidity across the continent, causing elephantiasis, river blindness, and eye worm, respectively \[[@CR1]--[@CR3]\]. Whilst loiasis is not yet included within the World Health Organization's (WHO) list of neglected tropical diseases (NTDs), LF and onchocerciasis are targeted by the WHO 2012 Roadmap on NTDs \[[@CR4]\] for elimination in selected African countries by 2020 using preventive chemotherapy. This strategy is implemented through community-wide mass drug administration (MDA), delivered yearly (and in some cases twice yearly) to all at-risk populations until transmission has been interrupted, combined with vector control measures where feasible \[[@CR4]\].

Large-scale MDA programmes, implemented locally in endemic communities but coordinated and supported regionally, have been ongoing in Africa for over 25 years, first for onchocerciasis \[[@CR5]\] and since 2000 for LF \[[@CR6]\]. These are widely considered among the most successful and cost-effective public health interventions ever launched \[[@CR5], [@CR7]\]. Nevertheless, there are important factors limiting their sustainability, including the availability of effective drug regimens that ensure a rapid interruption of transmission. For onchocerciasis, ivermectin has been the only drug used for MDA since Merck & Co. Inc. first announced its donation to endemic countries in 1987 \[[@CR8]\], whilst for LF the mainstay treatment is a combination of either diethylcarbamazine (DEC, donated by Eisai Co. Ltd) - in non-onchocerciasis endemic areas - or ivermectin, given annually, plus albendazole (donated by GlaxoSmithKline) \[[@CR9]\]. Although relatively safe and efficacious against microfilariae (mf, the larval progeny stage), these regimens are not considered to exert a powerful macrofilaricidal (adult stage killing) effect on the long-lived adult worms. Instead, ivermectin has a temporary sterilising effect on female *O. volvulus* \[[@CR10]\] and, in combination with albendazole, also on *W. bancrofti* \[[@CR11]\]). Thus in order to interrupt transmission, MDA must be continued, at high levels of treatment coverage and adherence \[[@CR12]\], for at least as long as the duration of the reproductive lifespan of the adult worms (ranging from 4 to 12 years for *W. bancrofti* \[[@CR13]\] and from 9 to 11 years for *O. volvulus*, with 95% of the worms ending reproduction by the age of 13 to 15 years \[[@CR14]\].

For filarial control programmes to be successful in shorter timeframes, regimens that kill or irreversibly sterilise adult worms are required \[[@CR15]\]. As an alternative to developing a new compound, it has been suggested that simultaneous provision of triple drug therapy (IDA; ivermectin + DEC + albendazole) may improve LF microfilarial clearance and further impact upon adult worms \[[@CR16]\]. A pilot study conducted in Papua New Guinea has reported that single dose IDA treatment rapidly eliminated all *W. bancrofti* mf from peripheral blood. Encouragingly, all participants treated with this regimen remained amicrofilaraemic for at least 2 years following treatment, suggesting sterilisation or killing of adult worms \[[@CR16]\]. Recent simulation modelling based on these findings has further suggested that the triple-drug regimen has potential to accelerate the elimination of LF, conditional on achieving high population coverage and low systematic non-adherence to MDA \[[@CR17]\]. To appreciate fully the potential of IDA for reducing the duration of MDA interventions against LF, it is imperative that these findings be replicated within larger trial settings.

Whilst IDA may help to accelerate the elimination of LF, it is important to delineate the settings where its use for MDA would be safe and appropriate \[[@CR18]\]. One major concern is the risk of severe adverse events (SAEs), which can arise following microfilaricidal medication. In the limited setting of the IDA pilot trial, adverse events were more common in those treated with the triple therapy, although no SAEs were recorded \[[@CR16]\]. This may have important implications for programme safety and compliance. DEC cannot be used in areas where onchocerciasis is present, because it induces a strong local inflammation in patients with ocular (*O. volvulus*) mf \[[@CR19]\]. Similarly, providing ivermectin or DEC to those with high *Loa loa* microfilarial loads has been associated with SAEs, including neurological sequelae and fatal encephalopathy \[[@CR20], [@CR21]\], precluding their use in forest areas throughout much of central Africa \[[@CR22]\]. This has led to the recommendation that twice-yearly albendazole be implemented together with distribution of long-lasting insecticidal nets for control of LF in *L. loa* co-endemic areas \[[@CR23]\]. Another aspect that may hamper the large-scale implementation of IDA in only-LF endemic areas is the risk for individuals migrating from onchocerciasis endemic areas, a frequent occurrence in central African countries. This risk could be mitigated somewhat by obtaining information about the history of residence of those individuals to be treated.

Unfortunately, albendazole alone does not kill *O. volvulus* macro- or microfilariae \[[@CR24]\], reducing the number of potential strategies for the control and elimination of onchocerciasis in *L. loa* co-endemic areas. This is particularly true in areas hypoendemic for *O. volvulus*, where the risk of SAEs in individuals with loiasis outweighs the benefits of deploying ivermectin MDA. Current guidelines, developed by the Mectizan® Expert Committee and the Technical Consultative Committee (MEC/TCC) of the African Programme for Onchocerciasis Control (APOC) recommend to test for *L. loa* infection and treat accordingly ('test-and-treat' protocols) when areas to be treated with ivermectin are suspected, or known to be endemic for loiasis \[[@CR25]\]. By this approach, the relatively small proportion of *L. loa-*infected individuals at risk of SAEs (those with \> 30,000 mf/ml) are identified and excluded from treatment with ivermectin \[[@CR20], [@CR26]\]. This can be difficult to implement in practice as the current gold standard for *L. loa* diagnosis (thick-smear microscopy) requires trained personnel in a central laboratory, and so results are not immediately available for decision-making.

These challenges have prompted two areas of research that together comprise an enhanced 'test and treat' strategy: novel diagnostics to enable rapid identification of those with high levels of *L. loa* infection in the field in real time \[[@CR27]--[@CR29]\]; and new filaricides to treat onchocerciasis without affecting *L. loa* \[[@CR30], [@CR31]\]*.* If ongoing development and field-testing are successful, *L. loa-O. volvulus* co-infected individuals at risk of SAEs could be excluded during ivermectin mass treatment campaigns, and instead treated with an alternative filariacide such as doxycycline \[[@CR32]\]. Additionally, a new strategy based on fine scale-mapping of loiasis in onchocerciasis co-endemic areas has also been suggested to improve targeting, on the basis that environmental changes and population movements may have changed the epidemiological scenario depicted by previous RAPLOA surveys \[[@CR33]\].

To facilitate adoption of these innovative MDA drug regimens, whilst ensuring the risk of SAEs is minimised, we must pay careful consideration to the co-distribution of these three filarial species. Large-scale surveys for each species have been conducted across most endemic areas in Africa, and geostatistical approaches have been used to predict the geographical distribution and endemicity levels prior to control \[[@CR34]--[@CR36]\]. The extent of spatial heterogeneity in co-distributions across the SSA region however is less clearly defined. Building upon previous work by Kelly-Hope et al. \[[@CR37], [@CR38]\], we present an initiative to use available, single-species spatial predictions to delineate co-distribution of these major filarial infections across SSA, enabling enumeration of target populations for different treatment schemes and quantification of populations potentially at-risk of SAEs.

Methods {#Sec2}
=======

Developing filariases co-endemicity maps for sub-Saharan Africa {#Sec3}
---------------------------------------------------------------

The mapping sources used to identify co-endemic filarial infection settings across the continent include contemporary maps of LF endemicity published by the WHO's Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) and published predictive risk maps for onchocerciasis \[[@CR34], [@CR39]\] and loiasis \[[@CR36]\] produced by the African Programme for Onchocerciasis Control (APOC). The latter are available together with other epidemiological resources at [www.ntdmap.org](http://www.ntdmap.org) \[[@CR40]\]. Several pragmatic adjustments were made to better adapt these pre-control predictive maps to the contemporary situation, as outlined below. In brief:(i)The current-day distribution of LF endemicity was obtained from the new NTD portal developed by ESPEN \[[@CR41]\] and from the Preventive Chemotherapy and Transmission Control (PCT) databank \[[@CR42]\]. According to WHO guidelines, programmatic implementation units (IUs; typically correspond to administrative areas such as districts) are declared as endemic for LF when at least 1 adult (≥ 15-yr) in 100 surveyed has a positive circulating filarial antigen (CFA) test or presents *W. bancrofti* mf in peripheral blood \[[@CR43]\]. For areas where endemicity status was unavailable, we used a risk map of predicted LF antigenaemia prevalence developed using geostatistical modelling approaches \[[@CR35]\]. Further details are given in Additional file [1](#MOESM1){ref-type="media"}: Text S1 and Figure S1.(ii)For onchocerciasis, we combined two published sources to generate an SSA-wide map. We used gridded maps of predicted prevalence at 5 × 5 km resolution continuous risk surface because, unlike LF, MDA is not always delivered to an entire implementation unit; instead, the eligible population only includes residents of communities considered at risk, namely living in transmission zones \[[@CR44], [@CR45]\] within the implementation unit. The first source considered was a map of the estimated prevalence of palpable nodules (onchocercomata) prior to the implementation of control interventions, developed for the region covered by APOC. With the exception of foci where onchocerciasis has been deemed eliminated (see below) all areas with nodule prevalence \> 5% (prior to the initiation of control activities) were considered to remain endemic and targetable for control, based on prevalence contour maps and likelihood of sustained local transmission \[[@CR34], [@CR44]\]. For West Africa, the region covered by the Onchocerciasis Control Programme in West Africa (OCP), endemicity was classified on the basis of a predictive map of microfilarial prevalence \[[@CR39]\]. The onchocerciasis foci considered by the WHO to have been eliminated in certain foci in Mali, Senegal (including the Gambia River Basin, Faleme River Basin and Bakoye River Basin) \[[@CR46], [@CR47]\], Nigeria \[[@CR48]\], Sudan and Uganda \[[@CR49]--[@CR51]\] and were masked out, although elsewhere transmission still persists \[[@CR52]--[@CR56]\].(iii)A gridded map of the estimated prevalence of eye worm history (EWH), obtained by interpolating rapid assessment procedure for *Loa loa* (RAPLOA) survey data conducted in 11 loiasis endemic countries, was used as an approximation to loiasis prevalence as described in detail elsewhere \[[@CR36]\]. The resulting map was stratified into three areas based on the empirical relationship between prevalence of EWH and high *L. loa* microfilarial loads (≥ 30,000 mf/ml; i.e. the threshold above which ivermectin-induced SAEs may be expected \[[@CR26]\]), namely, ≥ 40% EWH prevalence (high risk of SAEs), 20--40% EWH prevalence (lower SAE risk, but enhanced post-treatment monitoring required) and \< 20% EWH prevalence (negligible risk of SAEs) \[[@CR26]\].

Filarial co-endemicity was explored at IU level, the subnational administrative level considered for MDA interventions. A harmonized IU-level cartography was obtained from Geoconnect (<http://www.geoconnect.org/>). Overlaid maps were classified according to the co-endemicity classification shown in Table [1](#Tab1){ref-type="table"} and population estimates for 2015 produced using a gridded population density map for 2015 \[[@CR57]\]. Filarial transmission is not usually associated with large urban areas, and so urban areas (defined as areas with population densities ≥ 1000 persons/km^2^) and peri-urban areas (those with \> 250 persons/km^2^ within a 15 km distance from urban extension edge) were excluded. Otherwise, our approach assumes that, unless interruption of transmission has been confirmed, the boundaries for transmission remain as they were pre-control, despite reduced prevalence in areas receiving control.Table 1Potential mass drug administration (or test-and-treat) strategies according to the co-endemicity of filarial infections in AfricaOnchocerciasisLymphatic filariasis (LF)Loiasis, based on EWH^a^Non-endemicLow (\<  20%)Moderate (20--40%)^b^High (≥ 40%)Non-endemicEndemicDEC + ALB+IVMDEC + ALB+IVMIVM + ALB\
Enhanced^c^\
ATS: T&TALB (2/year) + ITN\
ATS: T&TNon-endemic--------EndemicEndemicIVM + ALBIVM + ALBIVM + ALB\
Enhanced\
ATS: T&TIVM + ALB +ITN (T&T)\
Enhanced & MM^d^\
ATS: T&TNon-endemicIVMIVMIVM\
Enhanced\
ATS: T&TATS: T&T\
Enhanced + MM^a^If assessment of loiasis is based on thick-smear or CellScope Loa, the alternative treatment strategy (ATS) of Test & Treat (T&T) will exclude those with \> 30,000 microfilariae/ml and will treat the remainder with ivermectin (IVM). Those excluded from IVM treatment can be offered doxycycline or albendazole twice a year^b^Re-assessment (by RAPLOA or by parasitological methods) if distance to area with high EWH prevalence is below certain threshold (i.e. 10 km)^c^The term 'Enhanced' refers to post-treatment monitoring of severe adverse events (SAEs). For interruption of transmission, the duration of treatment (e.g. number of rounds) will be determined in part by the level of pre-control LF and/or onchocerciasis endemicity. Treatment coverage (of the total population) should be at least 65% for LF and 80% for onchocerciasis; non-adherence to treatment should be minimised^d^Enhanced & MM (enhanced surveillance of potential loiasis-related SAEs and medical monitoring at the community for five day safter MDA treatment)*Abbreviations*: *ALB* albendazole, *ATS* alternative treatment strategy, *DEC* diethylcarbamazine, *EWH* eye worm history, *IVM* ivermectin, *ITN* insecticide-treated nets, *LF* lymphatic filariasis, *MDA* mass drug administration, *RAPLOA* rapid assessment procedure for *Loa loa*, *SAE* severe adverse event, *T&T* Test (for loiasis) and treat those not at risk of SAEs (quantify *L. loa* microfilaraemia and treat those with \< 30,000 mf/ml)

All data processing was conducted using ArcGIS 10.3 (ESRI, Redlands, CA, USA) and R v3.3.3 software. Gridded maps of filarial infections were combined to generate an output raster dataset of filarial co-endemicity. Population estimates were extracted by overlaying a gridded map of population density for 2015 \[[@CR57]\] with the co-endemicity reclassified map.

Results and discussion {#Sec4}
======================

The resulting maps and figures highlight substantial within-country heterogeneity in the distributions of the three filarial infections, suggesting that to achieve optimal impact safely, tailored treatment strategies need to vary between (and perhaps even within) existing IUs. Suggested treatment strategies for each co-endemicity setting are provided in Table [1](#Tab1){ref-type="table"}.

Aggregating the resulting population estimates (Additional file [1](#MOESM1){ref-type="media"}: Table S1) identifies 251 million people living in areas of LF and/or onchocerciasis transmission in SSA (see Additional file [1](#MOESM1){ref-type="media"}: Figure S2 for further details of the co-distributions of these two filarial nematode species). Of these, 81 million individuals across the continent live in LF mono-endemic areas and may be eligible for IDA (54% of whom live in eastern Africa), suggesting that this strategy could have a transformative impact across the region. A further 90.1 million live in areas targetable for ivermectin plus albendazole (LF endemic regions without high *L. loa*). Together, these two regimens bring substantial additional benefits due to the wider antiparasitic efficacy of combined albendazole and ivermectin, notably against strongyloidiasis, trichuriasis, enterobiasis and some epidermal parasitic skin diseases, including scabies \[[@CR58], [@CR59]\]. Lastly, of these 90.1 million, 79.7 million live in LF-onchocerciasis co-endemic areas, highlighting substantial opportunities for programme integration.

Our estimates clearly differ from figures provided by WHO on people requiring preventive chemotherapy in 2015 (PCT databank, WHO \[[@CR60]\]). This may be explained by the alternative source of demographic data used to generate estimates, and by a more precise delineation of onchocerciasis endemic areas based on the geostatistical models. However, it should also be noted that figures for LF endemicity in Middle Africa should be treated with some caution, due to recent observations of cross-reactivity of the immunochromatographic (ICT) test used in LF mapping surveys to *L. loa* infections \[[@CR61]--[@CR63]\]. As a result, some areas currently considered endemic for LF in Middle Africa may require re-evaluation, which may in turn lead to the shrinkage of the LF endemicity map for this region.

In total, only 4% of the SSA population living in areas at risk for onchocerciasis and/or LF live in high prevalence loiasis areas, although a further 5.7% live in areas of moderate transmission. Within high loiasis prevalence populations, we estimate between 197,000 and 1.2 million people to be at risk of ivermectin-associated SAEs, considering a minimum and maximum prevalence of very high intensity of loiasis infection (densities ≥ 30,000 mf/ml) of 2 and 12% respectively \[[@CR26]\]). Further national estimates are provided in Table S2 of Additional file [1](#MOESM1){ref-type="media"}. It is noteworthy that a third of the areas potentially at high risk of SAEs are currently reported as being under MDA treatment for LF and/or onchocerciasis (Fig. [1](#Fig1){ref-type="fig"}), according to data available at the ESPEN portal \[[@CR41]\]. This may have reduced the intensity of loiasis transmission in these areas and consequently, reduced the numbers at risk of SAEs in areas under treatment. There is evidence of persistent high transmission in loiasis endemic areas however, even after several years of intensive community-directed treatment with ivermectin (CDTi) \[[@CR64]\].Fig. 1Maps displaying areas currently under MDA treatment (hatched areas) which are co-endemic for loiasis and lymphatic filariasis (**a**) and loiasis and onchocerciasis (**b**). *Abbreviations*: CDTi, community directed treatment with ivermectin; EWH, prevalence of eye worm history; LF, lymphatic filariasis; MDA, mass drug administration; Oncho, onchocerciasis

Within these high loiasis areas, only a small proportion of the population requiring MDA would be suitable for targeting with twice-yearly albendazole (non-onchocerciasis endemic, LF endemic), confined primarily to Cameroon, Democratic Republic of Congo (DRC) and Central African Republic (CAR). The vast majority (close to 8.7 million people) are predicted to live in areas with onchocerciasis, where test-and-treat strategies are required (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Of these, 7 million also live in areas potentially co-endemic for LF (not accounting for possible over-diagnosis of LF in *L. loa* endemic areas).Fig. 2Suitable mass drug administration (MDA) and "Test & Treat" based schemes tailored to the type and level of co-endemicity of three major filarial infections in sub-Saharan Africa. The chart graph shows the overall population that may potentially benefit from different MDA schemes. *Abbreviations*: ALB, albendazole; DEC, diethylcarbamazine; E, enhanced post-treatment monitoring for rapid determination of potential loiasis-related SAEs; IVM, ivermectin; ITN, insecticide-treated nets; MDA, mass drug administration; MM, medical monitoring at the community during 3--4 days after MDA; R, regular monitoring of drug effects on treated communities; SAE, severe adverse eventTable 2Estimates of populations living in areas endemic for three major filariases in Africa, which may be targeted with tailored mass drug administration (MDA) schemes according to the level of co-endemicity of the filarial nematode speciesEstimates of populations living in areas potentially targetable with different MDA schemesIVM + ALBIVMIVM + ALB (E)^a^IVM (E)^a^ALB(2/year) + ITN^a^IVM + ALB + ITN (E + MM)^a^DEC + ALB + IVM^b^IVM (E + MM)^a^Eastern Africa8,413,86920,963,598--------45,192,922--Burundi--1,390,645------------Eritrea------------104,459--Ethiopia2,340,29614,392,313--------1,161,307--Kenya------------1,045,022--Madagascar------------13,557,237--Malawi--2,048,395------------Mozambique493,510742,771--------10,369,358--Rwanda--38,195------------Uganda1,426,5582,174,834--------992,624--Tanzania4,153,505176,445--------10,262,625--Zambia------------6,426,817--Zimbabwe------------1,273,473--Middle Africa17,259,69718,580,6707,040,6362,498,1321,381,5586,636,0624,154,0281,741,016Angola225,1045,670,871--111,4733232314116,774244,993Cameroon3,064,962435,4861,270,793245,554331,3631,548,497635,665251,586CAR555,2405358681,3913062697,014756,08060,60533,118Chad1,139,547857,065476,21225,770--211,614363,059--Congo37,7293026101,911576739,15429,24227,5899924DRC12,237,11511,608,8644,483,0372,104,428222,5333744,582,950,3351,038,597Equatorial Guinea----27,293--91,172343,735----Gabon------2078------162,798Northern Africa3,045,6723,046,221509,86918,85819,263208,3104,688,5648669South Sudan2,998,1362,969,800509,86918,85819,263208,310843,1508669Sudan47,53676,421--------3,845,414--Western Africa50,942,78823,619,5983,563,101724,325--21,27826,738,45272,050Benin1,821,0211,847,795--------97,670--Burkina Faso4,332,5285,527,801------------Ghana307,3962,030,355--------84,886--Guinea3,390,416227,213--------1,461,344--Guinea-Bissau176,095----------524,123--Liberia42,021----------1,964,905--Mali5,959,7676758--------2,861,263--Mauritania------------700,830--Niger78,987842,637--------4,837,755--Nigeria25,275,08310,052,1023,563,101724,325--21,2787,974,18772,050Senegal412,921----------2,883,203--Sierra Leone2,688,260----------683,589--Togo--2,670,471------------Côte d'Ivoire6,458,292414,466--------2,664,695--Grand total79,662,02666,210,08711,113,6053,241,3151,400,8226,865,65080,773,9661,821,736^a^Test & Treat (measure *Loiasis* microfilaraemia load before treatment and exclude those with \> 30,000 mf/ml)^b^Triple therapy with DEC is not yet recommended in countries where onchocerciasis is endemic. Re-evaluation of current endemicity is now considered in areas that were classified as hypoendemic by REMO mapping*Abbreviations*: *ALB* albendazole, *CAR* Central African Republic, *DEC* diethylcarbamazine, *DRC* Democratic Republic of Congo, *E* enhanced post-treatment monitoring for rapid determination of potential loiasis-related SAEs, *IVM* ivermectin, *ITN* insecticide-treated nets, *MDA* mass drug administration, *MM* medical monitoring at the community during 3--4 days after MDA; *SAE* severe adverse even

Considering the heterogeneity of disease distributions further, Fig. [3](#Fig3){ref-type="fig"} highlights the median number of MDA strategies required within countries and existing IUs. Only six endemic countries require just one MDA strategy, with the majority requiring up to four. For some countries in Middle Africa (including CAR and DRC) up to eight different strategies are indicated. Even within implementation units, more than one MDA strategy is suggested for just over half (1775/3564) of all endemic units due to fine scale spatial heterogeneity of transmission, with 653 implementation units across SSA (primarily in Cameroon, DRC, Chad, Congo and Nigeria) potentially requiring between three and eight strategies. These patterns are emphasised Additional file [1](#MOESM1){ref-type="media"}: Figures S3 and S4, further demonstrating how patterns of co-endemicity vary within very small geographical areas, and how this information might guide the tailoring of local treatment strategies.Fig. 3Variety of MDA schemes by country and implementation unit (IU) according to filariasis co-endemicity. The y-axis displays the number of IUs in which 1 to 8 different MDA schemes would be applicable according to the distribution and overlapping of loiasis, onchocerciasis and lymphatic filariasis

These maps are intended to initiate discussion around tailored treatment strategies, rather than to provide definitive recommendations. In particular, suggested recommendations for each IU presented here do not consider co-endemicity of other IUs, either in the same or in neighbouring countries. This is particularly important when considering whether an IDA-based MDA strategy is appropriate. It is notable that, when taking a stricter approach of only implementing triple drug therapy in countries non-endemic for onchocerciasis, the population that would benefit drops to 23,107,838 living across 6 countries.

Some important limitations should be acknowledged. First, the maps have been built upon predictive models using historic data. Each has an inherent degree of uncertainty, and should, wherever possible, be validated by national survey data. For example, nodule palpation for onchocerciasis can give false positive results in non-endemic areas \[[@CR65]\] and lack sensitivity in areas of low sensitivity \[[@CR66]\]. Nodule prevalence surveys were designed to delineate areas to be treated, namely, those with a nodule prevalence higher than 20% (indicative of at least mesoendemicity). Subsequently, for the purpose of elimination, it was agreed that the treatment boundaries need to be expanded to ensure that there remain no untreated onchocerciasis foci that might pose a future threat of reinfection. The nodule prevalence threshold below which we can assume there is no onchocerciasis transmission is still under discussion. Nevertheless, a 5% threshold has been suggested on the basis of non-onchocercal 'nodule' prevalence around 2% in endemic areas \[[@CR67]\]. Such assumption will require further investigation.

Recent parasitological surveys have shown many areas considered as hypoendemic no longer to be endemic \[[@CR68]\]. Furthermore, as noted above some areas highly endemic for loiasis in Middle Africa may require to be remapped for LF due to potential cross-reactivity of the ICT cards.

Secondly, the onchocerciasis and loiasis estimates reflect disease distribution prior to the scale up of mass treatment. Although efforts have been made to exclude areas considered as having interrupted transmission, we did not account for potential reduction on the intensity of loiasis transmission due to successive MDA rounds with ivermectin when estimating population potentially at-risk of suffering SAEs. Lastly, the incidence of loiasis-associated SAEs following ivermectin administration is seen to vary substantially within co-endemic areas \[[@CR69]\], which points to the existence of other as yet unidentified risk factors that require further exploration.

Conclusions {#Sec5}
===========

Substantial advances have been made towards the elimination of onchocerciasis and LF in SSA \[[@CR5], [@CR6]\]. Despite prolonged control activities however, many endemic areas are still experiencing ongoing transmission. Taken together with the risk of loiasis-related SAEs, issues of efficacy and appropriateness for existing treatment strategies remains of major concern. The work presented here highlights settings suitable for innovative MDA regimens and integrated control, which may help to address these concerns. Further work is required to test new strategies in programmatic settings, providing the empirical evidence needed to guide efforts towards the 2020 goals and beyond.
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